|1.||Baguley, Bruce C: 3 articles (04/2015 - 02/2009)|
|2.||Wu, Zimei: 2 articles (04/2015 - 10/2014)|
|3.||Zhang, Wenli: 2 articles (04/2015 - 10/2014)|
|4.||Shaw, John P: 2 articles (04/2015 - 10/2014)|
|5.||Wang, Guangji: 2 articles (04/2015 - 10/2014)|
|6.||Liu, Jianping: 2 articles (04/2015 - 10/2014)|
|7.||See, Esther: 2 articles (04/2015 - 10/2014)|
|8.||Amirapu, Satya: 1 article (04/2015)|
|9.||Svirskis, Darren: 1 article (10/2014)|
|10.||Xiong, G-Z: 1 article (10/2009)|
11/01/1996 - "Against advanced stage LC-12 (200-1000 mg tumors at initial treatment), combination therapy improved tumor cell kill by 0.6 log (4-fold) over that obtained with CI-921 therapy alone and also produced greater numbers of 120-day survivors than did single agent therapy with CI-921. "
10/01/2014 - "To facilitate the development of a liposomal formulation for cancer therapy, the physicochemical properties of asulacrine (ASL), an anticancer drug candidate, were characterized. "
02/01/1992 - "CI-921, an anilinoacridine compound active against leukemic and solid tumors, was evaluated for potential developmental toxicity. "
08/01/1987 - "CI-921 had significant activity against 16 of 19 (84%) tumor models examined. "
11/01/1996 - "Combination therapy against IV implanted P388 leukemia produced greater than 7.7 logs of net tumor cell kill, which was 630-fold greater (2.8 logs) than that obtained with CI-921 therapy alone. "
|2.||Lung Neoplasms (Lung Cancer)
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|5.||Lewis Lung Carcinoma
11/01/1985 - "Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma."
01/01/1986 - "Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921."
11/01/1985 - "The 4-methyl-5-(N-methyl)carboxamide derivative (CI-921; NSC 343499) of the clinical antileukaemia agent amsacrine is highly active towards P388 leukaemia and Lewis lung carcinoma in mice. "
01/01/1992 - "The sensitivity of three Lewis lung carcinoma sublines, which grow in culture and in vivo, and vary in in vivo drug sensitivity, have been compared using topoisomerase II poisons amsacrine, amsacrine analogue CI-921, doxorubicin and etoposide. "
|2.||Type II DNA Topoisomerases (Topoisomerase II)
|3.||DNA (Deoxyribonucleic Acid)
|5.||tranilast (N 5')
|8.||Etoposide (VP 16)
|10.||N- (2'- (dimethylamino)ethyl)acridine- 4- carboxamide
|1.||Drug Therapy (Chemotherapy)